PONTE
VEDRA, Fla., Feb. 8, 2023
/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD)
a biopharmaceutical company focused on developing tecarfarin, a
clinical-stage novel cardiorenal therapy with orphan drug and Fast
Track designations, today announced that Chairman and Chief
Executive Officer, Quang Pham, and
other Cadrenal team members will ring the Nasdaq Stock Market
closing bell on Wednesday, February 8,
2023.
"We are excited to ring the Nasdaq closing bell to commemorate
our recent IPO and announcement by the U.S. Food and Drug
Administration which granted a Fast Track designation to tecarfarin
for the prevention of systemic thromboembolism, or more commonly
referred to as blood clots, of cardiac origin in patients with
end-stage renal disease and atrial fibrillation," said Quang Pham, Chief Executive Officer of Cadrenal.
"These two important milestones help to advance our mission of
advancing patient care in cardiorenal diseases."
The Closing Bell ceremony will be broadcast live starting at
3:45 p.m. Eastern Time from the
Nasdaq MarketSite Tower in New York
City, New York. To view the
broadcast, please visit:
https://www.nasdaq.com/marketsite/bell-ringing-ceremony.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is focused on developing tecarfarin, a
novel cardiorenal therapy with orphan drug and Fast Track
designations for the prevention of systemic thromboembolism (blood
clots) of cardiac origin in patients with end-stage renal disease,
or ESRD, and atrial fibrillation (irregular heartbeat), or AFib.
Tecarfarin is a Vitamin K antagonist oral anticoagulant designed to
target a different pathway than the most commonly prescribed drugs
used in the treatment of thrombosis and AFib. Tecarfarin has been
evaluated in eleven human clinical trials and more than 1,000
individuals. In Phase 1, Phase 2 and Phase 2/3 clinical trials,
tecarfarin has generally been well-tolerated in both healthy adult
subjects and patients with chronic kidney disease. For more
information, please visit: www.cadrenal.com.
Safe Harbor Statement
Any statements contained in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
"forward-looking statements." These statements include statements
regarding looking to advancing patient care in cardiorenal
diseases. The words "anticipate," "believe," "continue,"
"could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "should," "target," "will,"
"would" and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including the
ability to advance the program to completion, the ability to
advance patient care in cardiorenal diseases and the other factors
discussed in the "Risk Factors" section of the initial public
offering prospectus filed with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof and, except as required by federal securities laws,
Cadrenal Therapeutics specifically disclaims any obligation to
update any forward-looking statement, whether as a result of new
information, future events or otherwise.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-ring-the-nasdaq-stock-market-closing-bell-on-february-8-2023-301741572.html
SOURCE Cadrenal Therapeutics, Inc.